Ascensión López Díaz de Cerio-rekin lankidetzan egindako argitalpenak (6)

2020

  1. Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

    British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073

2016

  1. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity

    Immunologic Research, Vol. 64, Núm. 2, pp. 548-557

2006

  1. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

    Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301

2004

  1. Past, present and future of anti-idiotype vaccination

    Revista de medicina de la Universidad de Navarra, Vol. 48, Núm. 3, pp. 14-23

2003

  1. Estrategias terapéuticas con vacunas idiotípicas en el tratamiento del linfoma folicular

    Hematologia - Citocinas, Inmunoterapia y Terapia Celular, Vol. 6, Núm. 3, pp. 175-182

  2. Feasibility of idiotype vaccination in relapsed B-cell malignancies

    Haematologica, Vol. 88, Núm. 12, pp. 1438-1440